IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$423.65 USD
-6.17 (-1.44%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$423.65 USD
-6.17 (-1.44%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
Why IDEXX Laboratories (IDXX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX Laboratories (IDXX).
IDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded first-quarter 2017 earnings per share (EPS) of 77 cents, up 51% (up 53% at constant exchange rate or CER) year over year on a reported basis.
IDEXX Laboratories (IDXX) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
IDEXX's first-quarter earnings per share came in at 77 cents, an increase of 51% year-over-year on reported basis. On a constant currency basis, this figure improved 53% year over year.
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
Investors may buy IDEXX Laboratories (IDXX) Ahead of Earnings depending on its decent Zacks Rank and earnings ESP in the positive territory.
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is slated to report first-quarter 2017 results on Apr 28, before the opening bell.
Becton (BDX) Gets FDA 510(k) for New Flow Cytometer System
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China.
Mazor Expects Higher Q1 Revenue, Receives Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report record first-quarter 2017 revenue of approximately $11.5 million compared with only $6.4 million in the year-ago quarter.
IDEXX Laboratories' CAG Revenues Solid, Competition Rife
by Zacks Equity Research
On Apr 5, we issued an updated research report on Delaware NJ-based IDEXX Laboratories, Inc. (IDXX).
Teleflex (TFX) Acquires Medical Device Provider Pyng Medical
by Zacks Equity Research
Teleflex Inc. (TFX), a global provider of medical technologies, announced that it has acquired Pyng Medical Corporation.
Becton, Dickinson Takes Over Caesarea Medical Electronics
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has acquired Caesarea Medical Electronics.
5 Stocks that Outperformed the S&P 500 in Q1
by Zacks Equity Research
First quarter was quite impressive and we have selected five top-ranked stocks that surpassed the S&P 500 index during the period.
Varian (VAR) Eclipse Software Tops in International Studies
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) recently announced that its Eclipse treatment planning software has topped in two competitive international plan studies.
PAREXEL (PRXL) Launches Sensor for Clinical Trial Market
by Zacks Equity Research
PAREXEL International Corporation (PRXL), a global biopharmaceutical services company and provider of clinical research and logistics, recently announced the launch of its patient sensor solution.
AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, reported adjusted earnings of 19 cents per share in the third quarter of fiscal 2017.
New Zacks Rank Strong Buy Stocks Breaking to Highs
by David Bartosiak
Today???s Daily Dive included a brief overview of the stellar action on crude oil, including intermediate term targets for the contract.
Envision (EVHC) Teams Up with Lyft to Focus on Transportation
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) recently announced that it has teamed up with on-demand transportation service provider Lyft.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
On Mar 29, we issued an updated research report on North Kansas City, MO-based Cerner Corporation (CERN) ??? a leading global provider of healthcare information technology solutions (HCIT).
Here's Why You Should Steer Clear of Mednax (MD) for Now
by Zacks Equity Research
Over the past 6 six months, shares of Mednax (MD) have gained 4.9%., underperforming the 9.8% increase logged by the Zacks categorized Medical - Hospital industry.
Intuitive Surgical Hits 52-Week High on Multiple Positives
by Zacks Equity Research
Shares of leading provider of robotic-assisted surgery, Intuitive Surgical, Inc. (ISRG) rallied to a new 52-week high of $770.28 on Mar 28, closing a tad lower at $764.47.
3 Medical Device Stocks to Brave Policy Uncertainty
by Zacks Equity Research
We believe stocks with strong fundamentals that also have a significant share of their business overseas may well brace themselves in the on-going conundrum. They will make lucrative additions to your portfolio.
IDEXX (IDXX) Poised on Strong Fundamentals, Innovations
by Zacks Equity Research
On Mar 14, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
ABIOMED Impella Heart Pump Reduces Kidney Injury during PCI
by Zacks Equity Research
A new study demonstrates that ABIOMED's flagship Impella 2.5 heart pump can reduce the risk of acute kidney injury during high-risk percutaneous coronary intervention (PCI).
Cooper Companies (COO) Receives ISO 15189 Accreditation
by Zacks Equity Research
The Cooper Companies Inc. (COO) announced that its London and Nottingham-based laboratories received the International Organization for Standardization 15189 accreditation.
C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain
by Zacks Equity Research
We issued an updated research report on C. R. Bard Inc. (BCR) on Mar 8, 2017.